Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
yzj-1139 + ticagrelor
- Development stage
- Unknown
- Lead developer
- Shanghai Haiyan Pharmaceutical Technology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**YZJ-1139 + ticagrelor** is a combination of two pharmaceutical drugs. - **YZJ-1139 (Fazamorexant)** is a small molecule dual orexin receptor antagonist developed for the treatment of insomnia disorder. It selectively blocks orexin type 1 (OX1R) and orexin type 2 (OX2R) receptors, inhibiting wake-promoting neuron activity and promoting rapid transition to sleep by increasing both REM and non-REM sleep maintenance[6][4][2]. - **Ticagrelor** is an oral P2Y12 receptor antagonist, classified as a platelet aggregation inhibitor and used to reduce the risk of cardiovascular death, myocardial infarction, stroke, and stent thrombosis in patients with acute coronary syndrome or a history of myocardial infarction[5][3][1]. The combination of these drugs does not represent an approved fixed-dose or branded combination; reports of combined usage mainly discuss research or therapy involving both agents.
- Other names
- Fazamorexant + ticagrelorticagrelor + YZJ-1139
02
Targets
HCRTR1 (Orexin/hypocretin receptor type 1)HCRTR2 (Orexin/hypocretin receptor type 2)
Beyond the preview
Go deeper on yzj-1139 + ticagrelor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on yzj-1139 + ticagrelor.